News

Under the terms of the agreement, BD Diagnostics-TriPath will develop, market and sell new biomarker-based diagnostic tests for certain cancers using Luminex’s multiplexing xMAP technology platform. BD develops

A major milestone was achieved earlier in 2008 with the completion of the Phase IIa, 28-day proof-of-concept trial for MB07803, said Metabasis. This clinical trial provided promising results

The Optima drug-eluting stent (DES) features a specially designed delivery system that allows for optimal DES expansion at implant. The registry will involve 1,000 patients throughout the world

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the company’s pivotal Phase II/III Canadian and European trial (Maestro-01) of

The exclusively licensed rights include US patents and pending applications. The license provides Sequenom with the exclusive right to use digital PCR methods on any platform for noninvasive

In conjunction with the postponement of negotiations with Prologue, Encorium’s management and board has initiated a strategic reorganization designed to cut costs and preserve capital. As an initial

The Fibrin Pad is said to be a breakthrough convergence product being developed by Omrix in collaboration with Ethicon, a Johnson & Johnson company. The Phase II clinical

Under the terms of the agreement between Alpharma’s affiliate, Alpharma Ireland Limited, and Durect, Alpharma will pay Durect an upfront license fee of $20 million, with possible additional

According to the company, the patent protects composite particles that can generate free radicals or heat when excited by X-rays, and to the uses thereof in health, particularly